TL;DR
Turn quiet afternoons into listening time
- Thousands of audiobooks, podcasts and originals
- Listen on your phone, tablet or Echo — also offline
- Cancel anytime
The U.S. Food and Drug Administration has approved the first wearable device that tracks both ketone and blood sugar levels in real-time. This innovation aims to improve diabetes management and metabolic health monitoring. The device’s approval marks a significant step forward in wearable health technology.
The U.S. Food and Drug Administration (FDA) has approved the first wearable device capable of simultaneously monitoring ketone and blood sugar levels in real-time. This device, developed by a medical technology company, represents a significant advancement in diabetes management and metabolic health monitoring. Its approval could influence future wearable health devices and provide patients with more comprehensive data to manage their conditions more effectively.
The device, called GluKet Tracker, is a compact, non-invasive wearable worn on the wrist. It uses advanced sensors to measure ketone levels, which are critical for individuals following ketogenic diets or managing diabetic ketoacidosis, alongside blood glucose levels, which are vital for diabetes control. The FDA approved the device based on clinical trials demonstrating its safety and accuracy in measuring both biomarkers.
According to the FDA, the device provides continuous, real-time data, alerting users to dangerous fluctuations in ketone or blood sugar levels. It is designed for people with diabetes, especially type 1 and type 2, as well as those on ketogenic diets or with metabolic disorders. The device pairs with a smartphone app, allowing users to track their levels over time and share data with healthcare providers.
Manufactured by MedTech Innovations, the GluKet Tracker received FDA approval under the de novo pathway, indicating it is a novel device with a low-to-moderate risk profile. The company announced plans to begin commercial distribution within the next few months, pending regulatory clearance in other markets.
Implications for Diabetes and Metabolic Health Monitoring
The FDA’s approval of the GluKet Tracker marks a milestone in wearable health technology, providing a tool that can improve disease management and potentially reduce complications associated with diabetes and ketosis. Real-time monitoring of both ketones and blood sugar offers a more comprehensive picture of metabolic health, enabling timely interventions. This development could lead to better patient outcomes, more personalized treatment plans, and increased adoption of integrated health monitoring devices. It also signals a shift toward more sophisticated, multi-biomarker wearables in the healthcare industry, potentially prompting further innovation and regulatory approvals in this space.wearable device for blood sugar and ketone monitoring
As an affiliate, we earn on qualifying purchases.
As an affiliate, we earn on qualifying purchases.
Development of Wearable Biomarker Monitoring Devices
Wearable health monitors have grown rapidly over the past decade, primarily focusing on heart rate, activity, and basic health metrics. However, monitoring specific biomarkers like ketones and blood glucose has remained limited to invasive methods such as finger-prick tests or continuous glucose monitors (CGMs).
The GluKet Tracker represents a new generation of wearables capable of non-invasively tracking multiple critical biomarkers simultaneously. Prior to this approval, several companies had developed prototype devices, but none had received formal regulatory approval for dual monitoring of ketones and glucose. The FDA’s decision reflects increasing recognition of the importance of comprehensive metabolic monitoring, especially for populations managing complex health conditions such as diabetes and ketogenic diets.
This approval aligns with broader trends toward personalized medicine and digital health solutions, emphasizing real-time data collection and remote health management. It also follows recent regulatory actions aimed at fostering innovation while ensuring safety and efficacy.
“This approval marks a significant step forward in wearable health technology, providing patients and healthcare providers with reliable, real-time data on critical metabolic biomarkers.”
— Dr. Lisa Monroe, FDA Medical Devices Director
non-invasive glucose and ketone tracker
As an affiliate, we earn on qualifying purchases.
As an affiliate, we earn on qualifying purchases.
Remaining Questions About Device Use and Adoption
It is not yet clear how widely the GluKet Tracker will be adopted, particularly among different patient populations. Long-term data on its accuracy, durability, and impact on health outcomes are still pending. Additionally, questions remain about insurance coverage and cost, which could influence accessibility for some users.real-time diabetes management wearable
As an affiliate, we earn on qualifying purchases.
As an affiliate, we earn on qualifying purchases.
Next Steps for Regulatory Approval and Market Launch
The manufacturer plans to begin commercial distribution within the next few months, pending final regulatory clearances in other countries. Further studies are expected to evaluate long-term safety, effectiveness, and user experience. Healthcare providers and patients will also need guidance on integrating this device into comprehensive diabetes management plans.
Regulatory bodies may monitor post-market data closely, and additional approvals or updates to device features could follow based on emerging evidence and user feedback.
FDA approved metabolic health monitor
As an affiliate, we earn on qualifying purchases.
As an affiliate, we earn on qualifying purchases.
Key Questions
How does the wearable device measure ketone and blood sugar levels?
The GluKet Tracker uses advanced sensors embedded in the wristband to detect biomarkers in sweat and interstitial fluid, providing continuous, non-invasive measurements of ketone and glucose levels.
Who can benefit from using this device?
Individuals with diabetes, especially type 1 and type 2, those on ketogenic diets, or with metabolic disorders can benefit from real-time monitoring of their ketone and blood sugar levels to better manage their health.
When will the device be available to consumers?
The manufacturer has announced plans to begin commercial distribution within the next few months, pending regulatory approvals and market preparations.
Is the device covered by insurance?
Insurance coverage details are still being finalized. It is unclear whether health insurers will reimburse for the device, which could affect accessibility for some users.
What are the limitations of the device?
While FDA approval confirms safety and accuracy, long-term data on durability and impact on health outcomes are still pending. Users should consult healthcare providers for personalized advice.
Source: hn
Halloween Picks
halloween
As an affiliate, we earn on qualifying purchases.
